Launch week offerEnds in00h00m00s

Iqbal Mahmud

Assistant Professor

Lamar University
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (11)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer, is largely incurable in the metastatic setting. ccRCC is characterized by excessive lipid accumulation that protects cells from stress and promotes tumor growth, suggesting that the underlying regulators of lipid storage could represent potential therapeutic targets. Here, we evaluated the regulatory roles of GPR1 and CMKLR1, two G-protein coupled receptors of the pro-tumorigenic adipokine chemerin that is involved in ccRCC lipid metabolism. Both genetic and pharmacological suppression of either receptor suppressed lipid formation and induced multiple forms of cell death, including apoptosis, ferroptosis and autophagy, significantly impeding ccRCC growth in cell lines and patient derived xenograft (PDX) models. Comprehensive lipidomic and transcriptomic profiling of receptor competent and depleted cells revealed overlapping and unique signaling of the receptors granting control over triglyceride synthesis, ceramide production, and fatty acid saturation and class production. Mechanistically, the receptors both enforced suppression of the triglyceride lipase ATGL but also demonstrated distinct functions, such as the unique ability of CMKLR1 to control lipid uptake through regulation of SREBP1c and the CD36 scavenger receptor. Treating PDX models with the CMKLR1-targeting small molecule α-NETA led to a dramatic reduction of tumor growth, lipid storage, and clear cell morphology. Together, these findings provide mechanistic insight into lipid regulation in ccRCC and identify a targetable axis at the core of the histological definition of this tumor that could be exploited therapeutically.

Year:

2024

Year:

2024

Year:

2023

Collaborators (9)

Scott M. Welford

Associate Professor

University of Miami

UNITED STATES
View details

Kai Sun

Associate Professor (tenured)

The University of Texas Health Science Center at Houston

UNITED STATES
View details

Oren Rom

Senior Associate Dean for Basic and Translational Research

LSU Health Shreveport

UNITED STATES
View details

Brian Law

University of Florida

UNITED STATES
View details

Sukwon Hong

Professor

Gwangju Institute of Science and Technology

SOUTH KOREA
View details

Weizhou Zhang

Vice Chair of Research/Dr. and Mrs. James Robert Spencer Professor of Pathology

University of Florida

UNITED STATES
View details

Nirav Dhanesha

Assistant Professor

-

UNITED STATES
View details

Konstantin Sokolov

Professor

-

UNITED STATES
View details

Nathan Fiore

Research scientist

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details